Get the Stockscreener App
4.85
6.73%
-0.35
After Hours:
4.85
Alvotech stock is traded at $4.85, with a volume of 458.00K.
It is down -6.73% in the last 24 hours and up +4.53% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$5.20
Open:
$5.19
24h Volume:
458.00K
Relative Volume:
0.93
Market Cap:
$1.51B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-2.6216
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
-4.72%
1M Performance:
+4.53%
6M Performance:
-43.08%
1Y Performance:
-61.75%
1-Day Range:
$4.83
$5.19
1-Week Range:
$4.83
$5.305
52-Week Range:
$4.32
$13.08
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
4.85 | 1.62B | 391.87M | -441.45M | -301.21M | -1.85 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares - Quiver Quantitative
Alvotech Announces Increase in Number of Own Shares - Chartmill
Assessing Alvotech (ALVO) Valuation After AVT80 Trial Success And New Sandoz Agreements - simplywall.st
Alvotech (ALVO) Investor Outlook: Exploring a 331% Potential Upside in the Biosimilars Market - DirectorsTalk Interviews
ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech - GlobeNewswire
Press releases provided by CNW - Techaeris
Aug Drivers: What is the Moat Score of Alvotech Equity WarrantQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Alvotech Faces Securities Claims Investigation - Intellectia AI
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - morningstar.com
Are Expanded Sandoz Biosimilar Deals Quietly Reframing Alvotech’s Partnership Strategy and Scale Ambitions (ALVO)? - simplywall.st
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio - MSN
Positive PK Results Put Alvotech’s Vedolizumab Biosimilar On Path Toward Filings - Citeline News & Insights
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
Private Equity Firms Are Alvotech's (NASDAQ:ALVO) Biggest Owners and Were Hit After Market Cap Dropped US$63m - 富途牛牛
Alvotech Hits Pivotal Milestone With Positive PK Data for Entyvio Biosimilar AVT80 - TipRanks
Alvotech (NASDAQ: ALVO) posts positive pivotal data for Entyvio biosimilar - Stock Titan
Alvotech Reports Positive Top-line Pharmacokinetic Study Results For AVT80, A Biosimilar To Entyvio - Nasdaq
Why Is ALVO Stock Rising Pre-Market Today? - Stocktwits
Alvotech (NASDAQ:ALVO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Alvotech Reports Positive Results for AVT80 Clinical Study - Intellectia AI
Fuji Pharma Lifts Sales Outlook but Slashes Profit Forecast on Alvotech Valuation Loss - TipRanks
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® - The Manila Times
Alvotech Announces Positive Top-Line Results from AVT80 Pharmacokinetic Study Compared to Entyvio® - Quiver Quantitative
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio - marketscreener.com
ROSEN, A LEADING NATIONAL FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - marketscreener.com
Alvotech (ALVO): A bull case theory - MSN
Alvotech (ALVO): A Bull Case Theory - Insider Monkey
Alvotech (ALVO) Growth Potential: A Deep Dive into Its 316.67% Upside and Biosimilar Innovations - DirectorsTalk Interviews
Is It Time To Reconsider Alvotech (ALVO) After Its Sharp Three-Year Share Price Slide? - simplywall.st
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - TMX Newsfile
Assessing Alvotech (ALVO) Valuation After Mixed Short Term Gains And A Steep One Year Decline - Yahoo Finance
Alvotech appoints Lisa Graver as CEO - Pharmafile
Chipmakers Recap: How does Alvotech score in quality rankingsMarket Performance Summary & Free Verified High Yield Trade Plans - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Trading Down 0.9%Should You Sell? - MarketBeat
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged ... - Bluefield Daily Telegraph
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates - wahanariau.com
Alvotech’s Volatile Climb: Can A High?Beta Biosimilar Pure?Play Win Back Investor Trust? - AD HOC NEWS
Death Cross: Is Alvotech stock overvalued or fairly pricedMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Alvotech Hooks Up With Sandoz For Biosimilars In Canada, Australia And New Zealand - Citeline News & Insights
Alvotech Strikes Sandoz Biosimilar Supply and Commercialization Deals in Canada, Australia and New Zealand - TipRanks
Alvotech (NASDAQ: ALVO) inks Sandoz biosimilar pacts for Canada, Australia and New Zealand - Stock Titan
Alvotech Signs Biosimilar Supply, Commercialization Deals with Switzerland's Sandoz - marketscreener.com
Alvotech Enters Supply, Commercialization Deal With Sandoz Covering Biosimilar Candidates - Nasdaq
Alvotech Enters Supply Agreements with Sandoz for Biosimilars - intellectia.ai
Alvotech Enters Supply and Commercialization Agreements with Sandoz for Multiple Biosimilar Candidates in Canada, Australia, and New Zealand - Quiver Quantitative
Bond Watch: What is the Moat Score of Alvotech Equity Warrant2025 Trading Volume Trends & Weekly Sector Rotation Insights - baoquankhu1.vn
Aug Levels: Is Alvotech stock showing strong momentum2025 Performance Recap & Low Drawdown Momentum Ideas - baoquankhu1.vn
How Investors May Respond To Alvotech (ALVO) Securing Global Rights For Its Eylea Biosimilar Launch - Sahm
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar - MSN
(ALVO) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):